期刊
BIOMARKER RESEARCH
卷 11, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s40364-023-00475-8
关键词
Hematological malignancies; Myeloid-derived suppressor cells; Immunosuppressive regulator; Tumor microenvironment; Immunotherapy
In this review, the biological functions, phenotypic characteristics, suppressive mechanisms, and expansion of MDSC populations in various types of hematological malignancies are summarized. The clinical correlation between MDSCs and the diagnosis of malignant hematological diseases, as well as the drugs targeting MDSCs, are discussed. Furthermore, the therapeutic strategies combining MDSCs targeting with other immunotherapies, such as immune checkpoint inhibitors, are highlighted.
The immunosuppressive tumor microenvironment (TME) supports the development of tumors and limits tumor immunotherapy, including hematological malignancies. Hematological malignancies remain a major public health issue with high morbidity and mortality worldwide. As an important component of immunosuppressive regulators, the phenotypic characteristics and prognostic value of myeloid-derived suppressor cells (MDSCs) have received much attention. A variety of MDSC-targeting therapeutic approaches have produced encouraging outcomes. However, the use of various MDSC-targeted treatment strategies in hematologic malignancies is still difficult due to the heterogeneity of hematologic malignancies and the complexity of the immune system. In this review, we summarize the biological functions of MDSCs and further provide a summary of the phenotypes and suppressive mechanisms of MDSC populations expanded in various types of hematological malignancy contexts. Moreover, we discussed the clinical correlation between MDSCs and the diagnosis of malignant hematological disease, as well as the drugs targeting MDSCs, and focused on summarizing the therapeutic strategies in combination with other immunotherapies, such as various immune checkpoint inhibitors (ICIs), that are under active investigation. We highlight the new direction of targeting MDSCs to improve the therapeutic efficacy of tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据